Works matching DE "IPILIMUMAB"
Results: 2399
Utility of Assessing Early Tumor Shrinkage as an Efficacy Predictor in Patients with Non-Surgically Indicated or Recurrent Esophageal Cancer Treated with Nivolumab plus Ipilimumab.
- Published in:
- Oncology, 2025, v. 103, n. 3, p. 167, doi. 10.1159/000540851
- By:
- Publication type:
- Article
Immune Checkpoint Blockade Response in Mucinous Tubular and Spindle Cell Carcinoma.
- Published in:
- Current Oncology, 2025, v. 32, n. 2, p. 94, doi. 10.3390/curroncol32020094
- By:
- Publication type:
- Article
Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 5, p. 222, doi. 10.1007/s40267-022-00915-9
- By:
- Publication type:
- Article
Enhancing anti‐PD‐1 Immunotherapy by Nanomicelles Self‐Assembled from Multivalent Aptamer Drug Conjugates.
- Published in:
- Angewandte Chemie, 2021, v. 133, n. 28, p. 15587, doi. 10.1002/ange.202102631
- By:
- Publication type:
- Article
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 5, p. 1687, doi. 10.1007/s10067-020-05420-w
- By:
- Publication type:
- Article
Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 6, p. 1697, doi. 10.1007/s00403-023-02577-7
- By:
- Publication type:
- Article
Tanshinol inhibits growth of malignant melanoma cells via regulating miR-1207-5p/CHPF pathway.
- Published in:
- Archives of Dermatological Research, 2020, v. 312, n. 5, p. 373, doi. 10.1007/s00403-019-01992-z
- By:
- Publication type:
- Article
Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
- Published in:
- Archives of Dermatological Research, 2014, v. 306, n. 6, p. 511, doi. 10.1007/s00403-014-1457-7
- By:
- Publication type:
- Article
Upcoming strategies for the treatment of metastatic melanoma.
- Published in:
- Archives of Dermatological Research, 2012, v. 304, n. 3, p. 177, doi. 10.1007/s00403-012-1223-7
- By:
- Publication type:
- Article
Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma.
- Published in:
- Eurasian Journal of Medical Investigation, 2022, v. 6, n. 4, p. 429, doi. 10.14744/ejmi.2022.79013
- By:
- Publication type:
- Article
American Association of Cancer Research Showcases Immunotherapy Advances.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 8, p. 4, doi. 10.1093/jnci/djv231
- By:
- Publication type:
- Article
PDQ (Physician Data Query).
- Published in:
- 2014
- Publication type:
- Abstract
Melanoma Treatment's Changing Landscape.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 6, p. 4, doi. 10.1093/jnci/dju176
- By:
- Publication type:
- Article
Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody.
- Published in:
- 2020
- By:
- Publication type:
- Letter to the Editor
Os ensaios clínicos e o registro de anticorpos monoclonais e biomedicamentos oncológicos no Brasil.
- Published in:
- Pan American Journal of Public Health / Revista Panamericana de Salud Pública, 2016, v. 39, n. 3, p. 149
- By:
- Publication type:
- Article
Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.
- Published in:
- Neurological Sciences, 2024, v. 45, n. 3, p. 1243, doi. 10.1007/s10072-023-07190-0
- By:
- Publication type:
- Article
Cytokines/chemokines and immune checkpoint molecules in anti-leucine-rich glioma-inactivated 1 encephalitis.
- Published in:
- Neurological Sciences, 2023, v. 44, n. 3, p. 1017, doi. 10.1007/s10072-022-06526-6
- By:
- Publication type:
- Article
Ipilimumab treatment associated with myasthenic crises and unfavorable disease course.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity.
- Published in:
- Journal of Immunology Research, 2022, p. 1, doi. 10.1155/2022/9764002
- By:
- Publication type:
- Article
Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Construction of Metabolic Molecular Classification and Immune Characteristics for the Prognosis Prediction of Ovarian Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609.
- Published in:
- Quality of Life Research, 2023, v. 32, n. 1, p. 183, doi. 10.1007/s11136-022-03226-8
- By:
- Publication type:
- Article
Implications and benefits of the NICE appraisal of pembrolizumab.
- Published in:
- British Journal of Healthcare Management, 2015, v. 21, n. 11, p. 506, doi. 10.12968/bjhc.2015.21.11.506
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 9, p. 370
- By:
- Publication type:
- Article
Immunotherapy Takes Center Stage in NCCN Advanced Melanoma Guideline.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 4, p. 172
- Publication type:
- Article
Case Presentation: International Focus on the Management of Acral Lentiginous Melanoma.
- Published in:
- Personalized Medicine in Oncology, 2015, v. 4, n. 1, p. 42
- Publication type:
- Article
Blocking Immune Checkpoints in Metastatic Melanoma.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 5, p. 275
- By:
- Publication type:
- Article
New Melanoma Guideline Adds BRAF Inhibitor, MEK Inhibitor to First-Line Systemic Therapy Options.
- Published in:
- Personalized Medicine in Oncology, 2014, v. 3, n. 3, p. 170
- By:
- Publication type:
- Article
Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-63403-2
- By:
- Publication type:
- Article
The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00261
- By:
- Publication type:
- Article
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00142
- By:
- Publication type:
- Article
Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors.
- Published in:
- Frontiers in Oncology, 2019, v. 9, p. 1, doi. 10.3389/fonc.2019.01101
- By:
- Publication type:
- Article
Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00425
- By:
- Publication type:
- Article
Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00403
- By:
- Publication type:
- Article
Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00084
- By:
- Publication type:
- Article
Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1.
- Published in:
- Frontiers in Immunology, 2014, v. 5, p. 1, doi. 10.3389/fimmu.2014.00206
- By:
- Publication type:
- Article
FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
- Published in:
- Clinical & Experimental Immunology, 2024, v. 216, n. 1, p. 68, doi. 10.1093/cei/uxad137
- By:
- Publication type:
- Article
Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer.
- Published in:
- Clinical & Experimental Immunology, 2022, v. 207, n. 3, p. 318, doi. 10.1093/cei/uxac007
- By:
- Publication type:
- Article
Mucosal‐associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy‐related colitis in a pathology distinct from ulcerative colitis.
- Published in:
- Clinical & Experimental Immunology, 2020, v. 202, n. 3, p. 335, doi. 10.1111/cei.13502
- By:
- Publication type:
- Article
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
- Published in:
- Ocular Immunology & Inflammation, 2022, v. 30, n. 6, p. 1449, doi. 10.1080/09273948.2021.1890133
- By:
- Publication type:
- Article
Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy.
- Published in:
- Lung Cancer: Targets & Therapy, 2022, v. 13, p. 53, doi. 10.2147/LCTT.S335117
- By:
- Publication type:
- Article
Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma.
- Published in:
- Case Reports in Urology, 2020, p. 1, doi. 10.1155/2020/8846135
- By:
- Publication type:
- Article
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
- Published in:
- Oncogene, 2015, v. 34, n. 43, p. 5411, doi. 10.1038/onc.2015.5
- By:
- Publication type:
- Article
Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
- Published in:
- Cell & Bioscience, 2018, v. 8, n. 1, p. N.PAG, doi. 10.1186/s13578-018-0229-z
- By:
- Publication type:
- Article
High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1181538
- By:
- Publication type:
- Article
Endocrine side effects of immune checkpoint inhibitors.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1157805
- By:
- Publication type:
- Article